- Home
- BSM vs NAMS Comparison
BSM vs NAMS Comparison
Compare BSM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- NAMS
- Stock Information
- Founded
- BSM 1876
- NAMS 2019
- Country
- BSM United States
- NAMS Netherlands
- Employees
- BSM N/A
- NAMS N/A
- Industry
- BSM Oil & Gas Production
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- NAMS Health Care
- Exchange
- BSM Nasdaq
- NAMS Nasdaq
- Market Cap
- BSM 2.6B
- NAMS 2.7B
- IPO Year
- BSM 2015
- NAMS N/A
- Fundamental
- Price
- BSM $11.97
- NAMS $27.00
- Analyst Decision
- BSM Hold
- NAMS Strong Buy
- Analyst Count
- BSM 1
- NAMS 10
- Target Price
- BSM $13.00
- NAMS $41.40
- AVG Volume (30 Days)
- BSM 503.2K
- NAMS 872.1K
- Earning Date
- BSM 11-03-2025
- NAMS 08-06-2025
- Dividend Yield
- BSM 10.03%
- NAMS N/A
- EPS Growth
- BSM N/A
- NAMS N/A
- EPS
- BSM 1.16
- NAMS N/A
- Revenue
- BSM $413,675,000.00
- NAMS $64,006,000.00
- Revenue This Year
- BSM $10.58
- NAMS N/A
- Revenue Next Year
- BSM $14.68
- NAMS N/A
- P/E Ratio
- BSM $10.28
- NAMS N/A
- Revenue Growth
- BSM N/A
- NAMS 762.15
- 52 Week Low
- BSM $11.90
- NAMS $14.06
- 52 Week High
- BSM $15.66
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BSM 39.85
- NAMS 67.63
- Support Level
- BSM $11.97
- NAMS $24.41
- Resistance Level
- BSM $12.24
- NAMS $25.65
- Average True Range (ATR)
- BSM 0.19
- NAMS 1.10
- MACD
- BSM 0.01
- NAMS 0.05
- Stochastic Oscillator
- BSM 12.26
- NAMS 98.63
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.